Clinical Trials Logo

Refractory Angina clinical trials

View clinical trials related to Refractory Angina.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05492110 Recruiting - Coronary Disease Clinical Trials

Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction.

REMEDY-PILOT
Start date: April 17, 2023
Phase: N/A
Study type: Interventional

To demonstrate the feasibility and efficacy of the CS Reducer for the treatment of patients with ischaemia and non-obstructed coronary arteries (INOCA) and coronary microvascular dysfunction (CMD) and through a nested mechanistic substudy investigate the physiological responses in the coronary microcirculation responsible for changes in myocardial perfusion.

NCT ID: NCT05102019 Recruiting - Refractory Angina Clinical Trials

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

COSIRA-II
Start date: January 4, 2022
Phase: N/A
Study type: Interventional

To demonstrate the safety and effectiveness of the Reducer system for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization. A non-randomized single-arm will further assess the safety and effectiveness of the Neovasc Reducer System in selected subjects with reversible myocardial ischemia in the distribution of the right coronary artery and who are deemed unsuitable for revascularization, subjects with reversible myocardial ischemia without documented obstructive coronary disease and subjects who cannot complete an exercise tolerance test due to an above-the-ankle amputation.

NCT ID: NCT04892537 Recruiting - Refractory Angina Clinical Trials

Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance

ORBITA-COSMIC
Start date: May 21, 2021
Phase: N/A
Study type: Interventional

ORBITA-COSMIC is a randomised, double-blinded, placebo controlled trial of the coronary sinus reducer (CSR). The investigators will compare the effects of CSR versus placebo on myocardial perfusion on MRI, exercise time and symptoms in 50 participants with refractory angina and ischaemia.

NCT ID: NCT04606459 Recruiting - Clinical trials for Coronary Microvascular Disease

COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina

COSIMA
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Patients with refractory microvascular angina fulfilling the predefined inclusion and exclusion criteria will be enrolled in this randomized trial. The primary objective is to investigate whether the proportion of patients reporting an improvement in Canadian Cardiovascular Society (CCS) angina class (≥2 classes) is different at six months after implantation of a Coronary Sinus Reducer followed by optimal medical therapy (OMT) compared to OMT alone.

NCT ID: NCT04368819 Recruiting - Refractory Angina Clinical Trials

Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms

ARAMIS
Start date: March 3, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Despite numerous advances in medical treatment and revascularization procedures for the treatment of patients with stable angina, debilitating symptoms that are unresponsive to conventional therapy may occur in patients unsuitable for revascularization, a condition known as refractory angina. Allopurinol, a methylxanthine oxidase inhibitor, is widely used in the treatment of gout and asymptomatic hyperuricemia. On the other hand, the anti-ischemic effects of allopurinol have been the subject of increasing interest. Therefore, the investigators will study the safety and efficacy of allopurinol in alleviating ischemic symptoms in patients with refractory angina already on optimal medical therapy.

NCT ID: NCT03991871 Recruiting - Clinical trials for Cardiac Rehabilitation

HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study

HARTEC
Start date: July 1, 2019
Phase: N/A
Study type: Interventional

External Counterpulsation Therapy (ECP) is a therapeutic procedure that performed on patients with angina or heart failure to relieve the ischaemic symptoms, improve functional capacity, and quality of life. In recent studies, ECP has already proved to reduce angina symptoms, decrease degree of ischemic in heart train test. External Counterpulsation Therapy (ECP) therapy is a non-invasive technique for sequentially pressuring calf, lower thighs, and upper thighs through developed cuffs at pressure above systolic blood pressure when diastole, then deflated at systole.

NCT ID: NCT03455725 Recruiting - Refractory Angina Clinical Trials

CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

CardiAMP CMI
Start date: June 30, 2021
Phase: N/A
Study type: Interventional

Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment Treatment Group: Subjects treated with aBMC using the CardiAMP cell therapy system Sham Control Group: Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)

NCT ID: NCT01566175 Recruiting - Refractory Angina Clinical Trials

Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization

Reducer
Start date: August 30, 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to implant the Reducer in patients with the symptoms of refractory angina, that suffer from refractory angina who demonstrate reversible ischemia.